Key result
D-4F restored the cardioprotective effect of anesthetic preconditioning during acute hyperglycemia, significantly reducing myocardial infarct size to 30% of the area at risk compared to 49% with hyperglycemia and preconditioning alone.
Why the study?
Does D-4F restore the cardioprotective effect of anesthetic preconditioning during acute hyperglycemia in preclinical models?
Does D-4F restore the cardioprotective effect of anesthetic preconditioning during acute hyperglycemia in preclinical models?
D-4F restores the cardioprotective effect of isoflurane-induced anesthetic preconditioning during acute hyperglycemia by enhancing eNOS signaling and NO biosynthesis.
Answers are grounded in this paper and cite their sources.
May enable anesthetic preconditioning in acute hyperglycemia; leaves open clinical translation.
Acute hyperglycemia (AHG) decreases the availability of nitric oxide (NO) and impairs anesthetic preconditioning (APC)-elicited protection against myocardial infarction. We investigated whether D-4F, an apolipoprotein A-1 mimetic, rescues the myocardium by promoting APC-induced endothelial NO signaling during AHG. Myocardial infarct size was measured in mice in the absence or presence of APC [isoflurane (1.4%)] with or without AHG [dextrose (2 g/kg ip)] and D-4F (0.12 or 0.6 mg/kg ip). NO production, superoxide generation, protein compartmentalization, and posttranslational endothelial NO synthase (eNOS) modifications were assessed in human coronary artery endothelial cells cultured in 5.5 or 20 mM glucose with or without isoflurane (0.5 mM) in the presence or absence of D-4F (0.5 μg/ml). Myocardial infarct size was significantly decreased by APC (36 ± 3% of risk area) compared with control (54 ± 3%) in the absence, but not presence, of AHG (49 ± 4%). D-4F restored the cardioprotective effect of APC during AHG (36 ± 3% and 30 ± 3%, 0.12 and 0.6 mg/kg, respectively), although D-4F alone had no effect on infarct size (53 ± 3%). Isoflurane promoted caveolin-1 and eNOS compartmentalization within endothelial cell caveolae and eNOS dimerization, concomitant with increased NO production (411 ± 28 vs. 68 ± 10 pmol/mg protein in control). These actions were attenuated by AHG (NO production: 264 ± 18 pmol/mg protein). D-4F reduced superoxide generation and enhanced caveolin-1 and eNOS caveolar compartmentalization and posttranslational eNOS modifications, thus restoring NO production during isoflurane and AHG (418 ± 36 pmol/mg protein). In conclusion, D-4F restored the cardioprotective effect of APC during AHG, possibly by decreasing superoxide generation, which promoted isoflurane-induced eNOS signaling and NO biosynthesis.
No takes yet. Share an insight, caveat, or question.
Baotić et al. (2013) studied Myocardial ischemia-reperfusion injury during acute hyperglycemia (n=70). D-4F (Apolipoprotein A-1 mimetic) vs. Vehicle control, acute hyperglycemia alone, or anesthetic preconditioning alone was evaluated on Myocardial infarct size (% of area at risk) (p=<0.05). D-4F restored the cardioprotective effect of anesthetic preconditioning during acute hyperglycemia, significantly reducing myocardial infarct size to 30% of the area at risk compared to 49% with hyperglycemia and preconditioning alone.
Synapse has enriched 10 related papers. Consider them for comparative context: